Targeted and ultrasound-triggered drug delivery using liposomes co-modified with cancer cell-targeting aptamers and a thermosensitive polymer

Ninomiya, Kazuaki; Yamashita, Takahiro; Kawabata, Shinya; Shimizu, Nobuaki

doi:10.1016/j.ultsonch.2013.12.023

Cited by 62 publications

(28 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This binding approach was adapted by Ninomiya et al to conjugate biotinylated aptamers on avidin-treated liposomes by avidin-biotin coupling (Figure 30), where an anti-platelet-derived growth factor receptor aptamer was surface-linked to doxorubicin-liposomes sensitized using poly (NIPMAM-co-NIPAM) as a thermosensitive polymer. Lower viability was observed against MDA-MB-231 breast cancer cell lines treated with doxorubicin-loaded aptamer-functionalized liposomes under ultrasound irradiation compared to cell viability without ultrasound irradiation [31].…”

Section: Avidin-biotin Couplingmentioning

confidence: 87%

Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

et al. 2019

View full text Add to dashboard Cite

Soon after they were first described in 1990, aptamers were largely recognized as a new class of biological ligands that can rival antibodies in various analytical, diagnostic, and therapeutic applications. Aptamers are short single-stranded RNA or DNA oligonucleotides capable of folding into complex 3D structures, enabling them to bind to a large variety of targets ranging from small ions to an entire organism. Their high binding specificity and affinity make them comparable to antibodies, but they are superior regarding a longer shelf life, simple production and chemical modification, in addition to low toxicity and immunogenicity. In the past three decades, aptamers have been used in a plethora of therapeutics and drug delivery systems that involve innovative delivery mechanisms and carrying various types of drug cargos. However, the successful translation of aptamer research from bench to bedside has been challenged by several limitations that slow down the realization of promising aptamer applications as therapeutics at the clinical level. The main limitations include the susceptibility to degradation by nucleases, fast renal clearance, low thermal stability, and the limited functional group diversity. The solution to overcome such limitations lies in the chemistry of aptamers. The current review will focus on the recent arts of aptamer chemistry that have been evolved to refine the pharmacological properties of aptamers. Moreover, this review will analyze the advantages and disadvantages of such chemical modifications and how they impact the pharmacological properties of aptamers. Finally, this review will summarize the conjugation strategies of aptamers to nanocarriers for developing targeted drug delivery systems. Molecules 2020, 25, 3 2 of 51 molecules [2]. Nowadays, the aptamer field covers various biomedical applications, including [3], therapeutic [4-6], aptasensors [7], biosensors [8,9], diagnostic [10,11], and imaging systems [12].Aptamers need to be stabilized for in vivo use against nuclease degradation, and their small size makes them susceptible to renal filtration. Aptamers' stabilization can be attained by chemically modifying them using different approaches. Moreover, introducing chemical modifications into nucleic acid libraries increases the interaction capabilities of aptamers and thereby their target spectrum [12]. Modified aptamers may show improved chemical diversity relative to aptamers composed entirely of natural DNA or RNA nucleotides and expand their applications in diagnostics, therapeutics, and nanotechnology [1].Chemical modifications of aptamer oligonucleotides are needed mainly to enhance their resistance to nuclease degradation and lowering their renal filtration. Additionally, chemical modifications, in some cases, may increase the aptamer-binding affinity [13]. Many approaches have been introduced to promote the stability of aptamers without altering their binding affinity and specificity against their targets. These approaches include chemical modification of the phosphate...

show abstract

Section: Avidin-biotin Couplingmentioning

confidence: 87%

Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Targeted and ultrasound-triggered liposomes co-modified with single stranded DNA aptamers can target platelet-derived growth factor receptors (PDGFRs) expressed in breast cancer cells. Poly (NIPMAM-co-NIPAM) as the thermosensitive polymer can sensitize these liposomes at high temperature [307]. Ideal ultrasound-mediated tumor-targeted drug carrier requires good drug stability in circulation, long drug retention until activated, small size allowing extravasation through defective tumor vasculature and high ultrasound responsiveness [308].…”

Section: Current Non-invasive Strategies For Cancer Treatmentmentioning

confidence: 99%

Novel delivery approaches for cancer therapeutics

Mitra

Agrahari

Mandal

et al. 2015

Journal of Controlled Release

130

View full text Add to dashboard Cite

Currently, a majority of cancer treatment strategies are based on the removal of tumor mass mainly by surgery. Chemical and physical treatments such as chemo- and radiotherapies have also made a major contribution in inhibiting rapid growth of malignant cells. Furthermore, these approaches are often combined to enhance therapeutic indices. It is widely known that surgery, chemo- and radiotherapy also inhibit normal cells growth. In addition, these treatment modalities are associated with severe side effects and high toxicity which in turn lead to low quality of life. This review encompasses novel strategies for more effective chemotherapeutic delivery aiming to generate better prognosis. Currently, cancer treatment is a highly dynamic field and significant advances are being made in the development of novel cancer treatment strategies. In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug targeting and ultrasound-mediated drug delivery, have added new modalities for cancer treatment. These approaches have led to selective detection of malignant cells leading to their eradication with minimal side effects. Lowering, multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer.

show abstract

“…Many of these use temperature-sensitive liposomes [8][9][10] that release the encapsulated drug upon ultrasound-induced mild hyperthermia of 40-42°C, a few degrees above physiological temperature [11][12][13][14]. Previous studies developed a new type of liposome for ultrasound-mediated drug release based on an emulsion containing liposomes (eLiposomes) that releases the encapsulated drug by an ultrasound-induced acoustic effect [15,16].…”

Section: Introductionmentioning

confidence: 99%

Targeted and ultrasound-triggered cancer cell injury using perfluorocarbon emulsion-loaded liposomes endowed with cancer cell-targeting and fusogenic capabilities

Ninomiya

Yamashita

Tanabe

et al. 2016

Ultrasonics Sonochemistry

Self Cite

View full text Add to dashboard Cite

This study investigated the targeting and ultrasound-triggered injury of cancer cells using anticancer drug-free liposomes that contained an emulsion of perfluoropentane (ePFC5) and were co-modified with avidin as a targeting ligand for cancer cells and the hemagglutinating virus of Japan (HVJ) envelope to promote liposome fusion with the cells. These liposomes are designated as ePFC5-loaded avidin/HVJ liposomes. ePFC5-loaded liposomes were sensitized to ultrasound irradiation. Liposomes modified with avidin alone (avidin liposomes) showed binding to MCF-7 human breast cancer cells, and liposomes modified with HVJ envelope alone (HVJ liposomes) were found to fuse with MCF-7 cells. The irradiation of MCF-7 cells with 1 MHz ultrasound (30s, 1.2 W/cm(2), duty ratio 30%) combined with ePFC5-loaded avidin/HVJ liposomes resulted in a decrease in cell viability at 1h after irradiation to 43% of that of controls without ultrasound irradiation or liposomes. The cell viability was lower than that of cells treated with ultrasound irradiation with ePFC5-loaded avidin liposomes or ePFC5-loaded HVJ liposomes. This indicates that co-modification of liposome with avidin and HVJ envelope could enhance ultrasound-induced cell injury in the presence of ePFC5-loaded liposomes.

show abstract

Targeted and ultrasound-triggered drug delivery using liposomes co-modified with cancer cell-targeting aptamers and a thermosensitive polymer

Cited by 62 publications

References 31 publications

Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

Aptamers Chemistry: Chemical Modifications and Conjugation Strategies

Novel delivery approaches for cancer therapeutics

Targeted and ultrasound-triggered cancer cell injury using perfluorocarbon emulsion-loaded liposomes endowed with cancer cell-targeting and fusogenic capabilities

Contact Info

Product

Resources

About